2162 logo

Keymed Biosciences SHSC:2162 Stock Report

Last Price

HK$31.75

Market Cap

HK$8.8b

7D

-5.6%

1Y

-33.5%

Updated

25 Dec, 2024

Data

Company Financials +

Keymed Biosciences Inc.

SHSC:2162 Stock Report

Market Cap: HK$8.8b

2162 Stock Overview

A biotechnology company, engages in the research and development of biological therapies for the treatment of autoimmunity and oncology diseases. More details

2162 fundamental analysis
Snowflake Score
Valuation4/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Rewards

Trading at 82% below our estimate of its fair value

Revenue is forecast to grow 50.32% per year

Analysts in good agreement that stock price will rise by 72.3%

Risk Analysis

Currently unprofitable and not forecast to become profitable over the next 3 years


My Notes

Capture your thoughts, links and company narrative

Keymed Biosciences Inc. Competitors

Beijing Biostar Pharmaceuticals

SEHK:2563

HK$11.9b

Shanghai Henlius Biotech

SEHK:2696

HK$13.0b

Shanghai Haohai Biological Technology

SEHK:6826

HK$13.7b

Alphamab Oncology

SEHK:9966

HK$3.3b

Price History & Performance

Summary of share price highs, lows and changes for Keymed Biosciences
Historical stock prices
Current Share PriceHK$31.75
52 Week HighHK$49.30
52 Week LowHK$26.60
Beta-0.060
1 Month Change-20.43%
3 Month Change-14.31%
1 Year Change-33.51%
3 Year Changen/a
5 Year Changen/a
Change since IPO-47.78%

Recent News & Updates

Recent updates

Shareholder Returns

2162HK BiotechsHK Market
7D-5.6%-2.7%1.5%
1Y-33.5%-9.2%20.6%

Return vs Industry: 2162 underperformed the Hong Kong Biotechs industry which returned -6% over the past year.

Return vs Market: 2162 underperformed the Hong Kong Market which returned 22.4% over the past year.

Price Volatility

Is 2162's price volatile compared to industry and market?
2162 volatility
2162 Average Weekly Movement8.5%
Biotechs Industry Average Movement11.5%
Market Average Movement8.8%
10% most volatile stocks in HK Market18.6%
10% least volatile stocks in HK Market4.0%

Stable Share Price: 2162 has not had significant price volatility in the past 3 months compared to the Hong Kong market.

Volatility Over Time: 2162's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20161,116Bo Chenwww.keymedbio.com

Keymed Biosciences Inc., a biotechnology company, engages in the research and development of biological therapies for the treatment of autoimmunity and oncology diseases. Its lead product candidate is CM310 for the treatment of moderate to severe atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), and chronic obstructive pulmonary disease (COPD). The company is also developing CM326, a monoclonal antibody targeting thymic stromal lymphopoietin to treat moderate-to severe AD, CRSwNP, asthma, and COPD.

Keymed Biosciences Inc. Fundamentals Summary

How do Keymed Biosciences's earnings and revenue compare to its market cap?
2162 fundamental statistics
Market capHK$8.75b
Earnings (TTM)-HK$790.80m
Revenue (TTM)HK$86.90m

100.7x

P/S Ratio

-11.1x

P/E Ratio

Is 2162 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2162 income statement (TTM)
RevenueCN¥81.65m
Cost of RevenueCN¥25.60m
Gross ProfitCN¥56.06m
Other ExpensesCN¥799.13m
Earnings-CN¥743.07m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-2.70
Gross Margin68.65%
Net Profit Margin-910.03%
Debt/Equity Ratio27.3%

How did 2162 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 21:24
End of Day Share Price 2024/12/24 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Keymed Biosciences Inc. is covered by 19 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jin ZhangChina International Capital Corporation Limited
Ziyu HeChina International Capital Corporation Limited
Wangbin ZhouChina International Capital Corporation Limited